Verify member benefits and PA rules with BCBSKS

Verify member benefits and prior authorization requirements with Blue Cross and Blue Shield of Kansas before ordering or billing any nontraditional biomarker tests; member contract language and state/federal mandates take precedence.

• Contact Blue Cross and Blue Shield of Kansas Customer Service to confirm coverage for the requested test and any prior authorization process.
• Codes listed in the policy are medically necessary ONLY if performed according to the Policy section and member contract.

PA expectation for experimental/investigational biomarker tests

Because the policy considers the listed novel lipid and non-lipid biomarkers and CVD risk panels experimental/investigational, anticipate denials or the need for prior authorization when ordering these tests to change management.

• Includes apolipoprotein B, apolipoprotein AI, apolipoprotein E, LDL/HDL subclasses, lipoprotein(a), BNP, cystatin C, fibrinogen, leptin, Lp-PLA2, and multimarker CVD panels.
• Expect payer processes to require clinical justification consistent with BCBSKS rules.

No PA specified in policy excerpt — verify per contract

The Policy text does not specify a standing prior authorization requirement for these biomarker tests within this excerpt; providers must still verify authorization per member contract.

• No explicit PA criteria are stated in the Policy excerpt.
• Verification with BCBSKS is required to determine if a PA is needed for billing.

No explicit PA criteria in this segment

This document segment does not list explicit prior authorization conditions for biomarker testing; clinical utility and evidence are emphasized rather than procedural authorization rules.

• Policy focuses on evidence of clinical utility rather than listing PA criteria in this section.
• Providers should not assume absence of PA — confirm with BCBSKS.

PA not specified — evidence summary only

The sections summarizing evidence do not include prior authorization rules—these are evidence summaries only; obtain PA guidance from BCBSKS prior to ordering.

• Evidence summaries state no PA language; clinical utility is the focus.
• Provider must check benefit coverage before ordering.

Clinical justification may be required when tests would change management

No clinical-authorization rules are provided here; because routine substitution of apo B or other apolipoproteins for standard lipid measures lacks demonstrated utility, expect payers to require clinical justification if used to direct therapy.

• Apo B may correlate with treatment response but no trials show improved outcomes when replacing LDL-C.
• If ordering to change management, document rationale showing expected management impact.

PA guidance for nontraditional biomarker testing when used to guide therapy

For nontraditional biomarker tests (APOE genotype, cystatin C, small dense LDL, Lp(a), Lp-PLA2), the policy notes lack of direct evidence to support guiding lipid-lowering therapy; prior authorization may be required if results are intended to change management.

• Policy identifies these tests as lacking direct evidence of outcome benefit.
• If test is being used to guide therapy, include documentation showing how results would alter treatment beyond standard assessment.

PA may be required for Lp‑PLA2 testing where utility is unestablished

Because randomized trial evidence of clinical utility for Lp‑PLA2 is absent, prior authorization may be required when Lp‑PLA2 testing is ordered to influence clinical management.

• No studies identified that assess clinical utility of Lp‑PLA2 to define CAD risk.
• Document how Lp‑PLA2 results would change management if seeking authorization.

Justify multimarker panel use — PA may be required

When ordering multimarker cardiovascular risk panels, be prepared to justify panel selection and demonstrate how results will alter treatment decisions beyond standard risk assessment; prior authorization may be required.

• No published studies evaluated commercially available CVD risk panels for impact on management or outcomes.
• Requests should explain why standard risk assessment is insufficient and how panel results will change care.

Use CAC thresholds to document and guide therapy decisions

Use coronary artery calcium (CAC) score thresholds in accordance with guideline-based implications: CAC ≥100 or ≥300 can inform initiation or intensification of statin/LDL‑C–lowering therapy; document how CAC results will guide therapy.

• CAC ≥100: initiation of statin therapy is recommended.
• CAC ≥300: consider high‑intensity statin and aggressive LDL‑C lowering.

PA and affected codes — confirm authorization before billing

The procedure and CPT/PLA codes listed in the Coding section (eg, 81291, 81401, 82172, 83695, 83698, 83704, 0052U, 0119U) are included for informational purposes and are medically necessary only when performed according to the Policy criteria; confirm prior authorization per member contract.

• Inclusion/exclusion of codes does not imply coverage or reimbursement.
• Verify authorization and medical necessity against Policy criteria and member benefits before billing.

References do not specify PA requirements

References and supplemental sections do not provide prior authorization requirements; they are citation lists and do not substitute for payer authorization processes.

• References section contains no PA or code lists.
• Providers must follow BCBSKS PA procedures rather than relying on reference text.

Reference lists do not establish PA rules — verify with payer

References do not state specific PA requirements for biomarker testing; verify benefits and any PA steps with BCBSKS.

• Reference lists are for background and do not define coverage rules.
• Check member contract for any PA or coverage limitations.

No step therapy rules specified

No step therapy requirements or mandates are specified in the Policy excerpt for biomarker testing; the Policy emphasizes standard risk management rather than step-therapy algorithms.

• No step-therapy mandates are described for apolipoprotein or APOE testing.
• Standard therapies remain preferred initial management regardless of APOE genotype.

No step‑therapy mandates; use guideline care before novel tests

The Policy contains no step‑therapy mandates for biomarker testing; consider ensuring guideline‑directed standard care is in place before approving novel biomarker testing.

• Ensure management of clinical risk factors with or without simple lipid testing prior to novel testing.
• No step‑therapy requirements are specified in reference lists.

No step-therapy mandates for apolipoprotein/APOE testing

The Policy does not impose step-therapy mandates for apolipoprotein or APOE testing; clinicians should follow standard lipid-management pathways and guideline‑directed care.

• Dietary modification and statins remain preferred initial management.
• Ordering novel biomarkers should not replace guideline‑directed initial therapy.

Use standard risk assessment first before novel biomarkers/panels

Standard risk‑factor management and simple lipid testing should be performed first; ensure guideline-directed care (eg, pooled cohort equations, lipid panel) before considering novel biomarker tests or panels.

• Use standard risk assessment tools prior to ordering novel biomarkers.
• Document why standard assessment is insufficient when seeking authorization for additional testing.

Escalate lipid‑lowering therapy when elevated Lp(a) influences risk

In high‑risk patients with elevated Lp(a) (eg, ≥125 nmol/L or ≥50 mg/dL), consider intensifying LDL‑C lowering and adding ezetimibe or a PCSK9 inhibitor if on‑treatment LDL‑C remains above targets; document rationale if these management changes are informed by Lp(a).

• NLA: Lp(a) ≥125 nmol/L (≈50 mg/dL) may be used as a risk‑enhancing factor to favor statin initiation or intensification.
• For high‑risk patients with Lp(a) ≥125 nmol/L on maximal statin, consider ezetimibe or PCSK9 inhibitor when on‑treatment LDL‑C ≥70 mg/dL.

Verify member benefits with BCBSKS customer service

Verify member benefits with Blue Cross and Blue Shield of Kansas Customer Service to determine coverage applicability for biomarker testing and any associated services (eg, genetic counseling).

• Member contract provisions take precedence over Medical Policy.
• Codes listed are informational — confirm coverage and PA requirements with BCBSKS.

Recommend formal genetic counseling before genetic testing

If genetic testing (eg, APOE genotyping) is being considered, obtain formal genetic counseling prior to testing and check member contract benefits for coverage of counseling services.

• Genetic counseling is recommended by experts to help interpret results and implications for patients and families.
• Confirm whether genetic counseling is a covered benefit under the member's contract.

Include study methodologic details when justifying testing

When evaluating evidence or seeking authorization for tests, include methodologic study details: marketed test version, reference standard, sensitivity/specificity, predictive values, and reclassification metrics per the Policy's study‑selection expectations.

• Studies should report true/false positives and reclassification of risk categories.
• Include validation cohort information and sample selection criteria when citing evidence.

Document LDL particle numeric targets if used to guide care

Suggested LDL particle concentration targets (from Framingham‑derived percentiles) are 1100, 1400, and 1800 nmol/L for the 20th, 50th, and 80th percentiles respectively; if using LDL particle data to inform management, document target rationale.

• These proposed targets correspond to ATP III percentile-based comparators.
• Document how particle concentration targets would change management decisions.

Document how test results will impact management and outcomes

Studies and documentation should demonstrate how biomarker or panel results would change clinical management and lead to improved net health outcomes; absence of such documentation is a basis for noncoverage.

• Direct evidence (RCTs) comparing management with and without testing is preferred to demonstrate clinical utility.
• If RCTs are unavailable, robust decision models or validated prediction models must show meaningful management changes and outcome benefit.

Monitor apo B every 6–12 weeks on statin therapy until targets met

For patients on statin therapy, monitor apo B (when used) every 6–12 weeks until treatment targets are achieved, then reduce monitoring frequency; document monitoring plans when ordering apo B for treatment response.

• AACE defines apo B targets: <90 mg/dL (high risk), <80 mg/dL (very high), <70 mg/dL (extreme risk).
• Monitoring frequency recommended every 6–12 weeks while titrating therapy.

Denial triggers — experimental/investigational tests and panels

Tests or panels that lack evidence demonstrating that results change management to improve health outcomes (including APOE, cystatin C, LDL particle size/number, Lp(a), Lp‑PLA2, and multimarker panels) are at risk for denial as not medically necessary.

• Policy explicitly labels these biomarkers and panels as experimental/investigational.
• Absence of RCTs or validated decision models showing outcome benefit supports denial.

No explicit authorization or billing denial language in evidence sections

No specific procedural or coding authorization/denial criteria are stated in the evidence sections; policy focuses on clinical utility and evidence rather than explicit billing denials—confirm payer rules before billing.

• Evidence summaries do not specify coding authorization rules.
• Providers must consult BCBSKS for specific billing or denial policies.

Supplemental references do not imply endorsement or PA rules

When supplemental information or references are cited, recognize inclusion is for reference only and does not imply endorsement or that PA is unnecessary; follow BCBSKS authorization rules.

• Supplemental/reference sections do not contain PA language and do not override policy determinations.
• Providers must obtain PA per member contract despite references being listed.

Coding disclaimers — codes do not imply coverage

Inclusion or exclusion of a CPT/PLA/procedure code in the Policy coding list does not guarantee member coverage or reimbursement; codes are medically necessary only when services meet Policy criteria and member contract terms.

• Always verify coverage and PA per the member's contract before billing.
• Coding list is informational and not a coverage guarantee.